In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercialization Alternatives In The New Medtech World

Executive Summary

In the current medtech environment, much attention is paid to evolving strategies to deal with the new challenges private companies are facing in areas like financing and regulatory, and a company’s sales strategy can be left for last or thought to be a topic for an acquirer. The authors describe the challenges that are emerging in the current medtech climate that make an early choice of a sales approach – from a variety of options – an important part of a company’s overall strategy. Not only can the choice of a viable commercialization strategy help drive revenue, it also can increase a company’s valuation at exit.

You may also be interested in...



Coronavirus Update: Moderna Set For Bigger Test As Vaccine Trials Begin In Older People

Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.

Digital Therapeutics Have Arrived But Will Insurers Get On Board?

Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.

NASH Backlash: Intercept Delay Raises Questions

A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel